摘要
胃癌是全球最常见的恶性肿瘤之一。胃癌患者采用传统的手术、放射治疗、化学治疗临床获益有限,5 a生存率不甚理想。近年来,程序性死亡受体-1/程序性死亡受体配体-1抑制剂联合细胞毒性T淋巴细胞相关蛋白4抑制治疗胃肿瘤的研究较多且取得了重大进展,已成为胃癌治疗的一种新手段。肿瘤干细胞在胃癌的发生、发展过程中发挥着至关重要的作用,其富聚多种肿瘤特异性抗原及特异性分子标志物,靶向肿瘤干细胞,可产生有效的抗肿瘤效应。免疫治疗已在多种肿瘤的研究中取得进展,在胃癌治疗中也获得了突破,其可能是临床上治疗胃癌的一种有效策略。本研究就近年来胃癌干细胞及免疫检查点抑制剂治疗胃癌的研究进展作一综述。
Gastric cancer is one of the most common malignant tumors in the world.The clinical benefits of traditional surgery,radiotherapy and chemotherapy in patients with gastric cancer are limited,and the 5-year survival rate is not ideal.In recent years,there have been many studies on programmed death receptor-1/programmed death receptor ligand-1 inhibitor combined with cytotoxic T lymphocyte associated protein 4 inhibitor for gastric tumors and made great progress,and it has become an effective new method for the treatment of gastric cancer.Gastric stem cells play a vital role in the occurrence and development of gastric cancer.Gastric cancer stem cells accumulate a variety of tumor-specific antigens and specific molecular markers,targeting cancer stem cells,which can produce effective anti-cancer drugs.Immunotherapy has made great progress in the research of many kinds of tumors and made a breakthrough in the treatment of gastric cancer.It may be an effective strategy for clinical treatment of gastric cancer.This study reviewed the research progress of gastric cancer stem cells and immune checkpoint inhibitors for gastric cancer in recent years.
作者
黄玉斌
刘霄
徐翠香
黄晓燕
王建华
HUANG Yubin;LIU Xiao;XU Cuixiang;HUANG Xiaoyan;WANG Jianhua(Xi′an Medical University,Xi′an 710021,Shaanxi Province,China;The Second Department of General Surgery,Shaanxi Provincial People′s Hospital,Xi′an 710068,Shaanxi Province,China;Shaanxi Key Laboratory of Infection and Immune Diseases,Shaanxi Provincial People′s Hospital,Xi′an 710068,Shaanxi Province,China)
出处
《新乡医学院学报》
CAS
2022年第5期486-490,495,共6页
Journal of Xinxiang Medical University
基金
国家自然科学基金青年科学基金项目(编号:81900686)
重点产业创新链(群)-社会发展领域项目(编号:2021ZDLSF01-07)。
关键词
胃癌
胃癌干细胞
免疫治疗
免疫检查点抑制剂
gastric cancer
gastric cancer stem cell
immunotherapy
immune checkpiont inhibitor
